These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27311182)

  • 21. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevention of surgical site infection for orthopaedic surgery in rheumatoid arthritis].
    Saitoh M; Matsushita K
    Nihon Rinsho; 2016 Jun; 74(6):993-9. PubMed ID: 27311191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tofacitinib for the treatment of rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2016 Jun; 74(6):974-80. PubMed ID: 27311188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Against parenteral gold therapy in rheumatoid arthritis].
    Kellner H
    Dtsch Med Wochenschr; 2011 Aug; 136(33):1677. PubMed ID: 21833892
    [No Abstract]   [Full Text] [Related]  

  • 26. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The issue of bioavailability of oral low dose methotrexate: should we choose only 10 mg of MTX a week in conjunction with anti-TNF therapy?
    Zeidler H
    Ann Rheum Dis; 2014 Aug; 73(8):e50. PubMed ID: 24764450
    [No Abstract]   [Full Text] [Related]  

  • 28. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D; Tanaka Y; Fleischmann R; Keystone E; Kremer J; Zerbini C; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Wyman BT; Gruben D; Benda B; Wallenstein G; Krishnaswami S; Zwillich SH; Bradley JD; Connell CA;
    Arthritis Rheum; 2013 Mar; 65(3):559-70. PubMed ID: 23348607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Indications for and use of biologics in early rheumatoid arthritis based on the evidence].
    Takeuchi T
    Nihon Rinsho; 2009 May; 67(5):1043-9. PubMed ID: 19432131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis.
    Koduri GM; Mukhtyar C
    Rheumatology (Oxford); 2019 Apr; 58(4):559-560. PubMed ID: 29672739
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication.
    Kawahito Y; Morinobu A; Kaneko Y; Kohno M; Hirata S; Kishimoto M; Seto Y; Sugihara T; Tanaka E; Ito H; Kojima T; Matsushita I; Nishida K; Mori M; Murashima A; Yamanaka H; Nakayama T; Kojima M; Harigai M
    Mod Rheumatol; 2023 Jan; 33(1):21-35. PubMed ID: 35297492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Tanaka Y; Suzuki M; Nakamura H; Toyoizumi S; Zwillich SH;
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1150-8. PubMed ID: 21584942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
    Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
    J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
    Albrecht K; Krüger K; Wollenhaupt J; Alten R; Backhaus M; Baerwald C; Bolten W; Braun J; Burkhardt H; Burmester GR; Gaubitz M; Gause A; Gromnica-Ihle E; Kellner H; Kuipers J; Krause A; Lorenz HM; Manger B; Nüßlein H; Pott HG; Rubbert-Roth A; Schneider M; Specker C; Schulze-Koops H; Tony HP; Wassenberg S; Müller-Ladner U;
    Rheumatol Int; 2014 Jan; 34(1):1-9. PubMed ID: 23942828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.
    Mease P; Strand V; Shalamberidze L; Dimic A; Raskina T; Xu LA; Liu Y; Smith J
    Ann Rheum Dis; 2012 Jul; 71(7):1183-9. PubMed ID: 22328739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.
    Takeuchi T; Matsubara T; Nitobe T; Suematsu E; Ohta S; Honjo S; Abe T; Yamamoto A; Miyasaka N;
    Mod Rheumatol; 2013 Mar; 23(2):226-35. PubMed ID: 22684431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rheumatoid arthritis: milestones in classification and treatment].
    Fiehn C
    Dtsch Med Wochenschr; 2011 Feb; 136(5):203-5. PubMed ID: 21271482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New options for the practice : Update S1/S2 guidelines on rheumatoid arthritis?].
    Schneider M
    Z Rheumatol; 2017 Mar; 76(2):125-132. PubMed ID: 28102443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.